HER2-Positive Breast Cancer in 2026: The Treatment Map Is Getting More Complicated

https://www.medscape.com/c99/p10/her2-positive-breast-cancer-2026-treatment-map-getting-more-2026a10011sr?src= Treatment for early HER2-positive breast cancer is moving in two directions. For some patients, the question is how much therapy can safely be stripped away — and the data increasingly support doing so. At the other end of the risk spectrum, new data are supporting treatment escalation for patients with high-risk disease or residual invasive disease after neoadjuvant therapy.